NYSE: MDTMedtronic PLC Stock
$79.48+0.29 (+0.37%)
Updated Apr 19, 2024
MDT Price
$79.48
Fair Value Price
N/A
Market Cap
$105.54B
52 Week Low
$68.84
52 Week High
$92.02
P/E
25.23x
P/B
2.04x
P/S
3.56x
PEG
0.91x
Dividend Yield
3.47%
Revenue
$32.32B
Earnings
$4.20B
Gross Margin
65.5%
Operating Margin
19.19%
Profit Margin
13%
Debt to Equity
0.75
Operating Cash Flow
$6B
Beta
0.82
Next Earnings
May 23, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MDT Overview
Medtronic plc manufactures device-based medical therapies. The company's Cardiovascular segment offers implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, cardiac ablation products, insertable cardiac monitor systems, TYRX products, and remote monitoring and patient-centered software. Its Medical Surgical segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence, and robotic-assisted surgery products. Medtronic was founded in 1949 and is headquartered in Dublin, Ireland.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDT ($79.48) is trading above its intrinsic value of $47.76, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDT is good value based on its earnings relative to its share price (25.23x), compared to the US market average (40.51x)
P/E vs Market Valuation
MDT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MDT due diligence checks available for Premium users.
Be the first to know about important MDT news, forecast changes, insider trades & much more!
MDT News
Valuation
MDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
25.23x
Industry
28.69x
Market
40.51x
MDT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MDT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.04x
Industry
3.63x
MDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDT price to earnings growth (PEG)
For valuing profitable companies with growth potential
MDT is good value based... subscribe to Premium to read more.
PEG Value Valuation
MDT's financial health
Profit margin
Revenue
$8.1B
Net Income
$1.3B
Profit Margin
16.3%
MDT's Earnings (EBIT) of $6.20B... subscribe to Premium to read more.
Interest Coverage Financials
MDT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$90.8B
Liabilities
$38.8B
Debt to equity
0.75
MDT's short-term assets ($22.51B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDT's long-term liabilities ($29.05B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.5B
Investing
-$707.0M
Financing
-$1.5B
MDT's operating cash flow ($6.47B)... subscribe to Premium to read more.
Debt Coverage Financials
MDT vs Medical Device Stocks
Medtronic Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.